BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, with lead programs in metastatic breast cancer and next-generation off-the-shelf personalized immunotherapies.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, with FDA Fast Track designation; additional programs include Bria-OTS™ and Bria-PROS+™ for breast and prostate cancer.

• Recent clinical data show promising efficacy and safety in heavily pretreated and ADC-resistant breast cancer patients, including those with CNS metastases.

• Strategic collaborations with BeiGene and Incyte for combination therapies and clinical supply agreements.

Financial performance and metrics

• For the six months ended January 31, 2025: $9.35M in R&D expenses and $2.97M in G&A expenses; net loss of $12.17M.

• Cash and cash equivalents as of January 31, 2025: $5.01M (actual), $16.25M (as adjusted for recent offerings and this IPO).

• Share consolidation (1-for-15) effective January 24, 2025, to maintain Nasdaq listing compliance.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.84M (or $10.22M if over-allotment is exercised) to fund working capital, general corporate purposes, and advancement of business objectives.

• Management has broad discretion over use of proceeds; specific allocations not detailed.